Clinical trials have shown that patients using Semaglutide can achieve substantial weight reduction, often ranging from 15% to 20% of their initial body weight over a period of 68 weeks
Conclusion The GLP-1 drug market is rapidly expanding, driving strong enthusiasm among companies for the development of GLP-1 medications
However, there are some exceptions that should be considered as well
What the authors are really pushing for is a validation framework built on biological relevance and mechanistic fit, not just concordance with animal data that is itself variable
Mariah, DNP AGNP-BC, RN, and Michael Scheker: Mariah Scheker is a devoted wife, mother, and Doctor of Nursing Practice (DNP) as a Board Certified Adult-Gerontology Nurse Practitioner (AGNP-BC) who brings heart, compassion, and deep clinical expertise to IV Nutrition Carmel as the Owner and Clinical Director